Synosia, UCB deal

Synosia granted UCB exclusive, worldwide rights to Parkinson's disease candidate SYN-115, an oral adenosine A2A receptor (ADORA2A) inhibitor. UCB also received an option to license PD candidate SYN-118, a 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor. Both compounds are in Phase II testing. Synosia will be responsible for Phase II development, while UCB will be responsible for Phase III development and commercialization. Synosia will receive an undisclosed upfront payment and, if the option is exercised, is eligible for up to $725 million in milestones, plus royalties. As part of the deal, UCB also made a $20 million investment in Synosia's $30 million series C round. ...